Davern Capital Partners, LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), Davern Capital Partners, LP reported 14 stock positions worth $309.3 million. Its top holding was Pfizer (PFE) at 16.4% of the portfolio, followed by Regeneron Pharmaceuticals (REGN, 13.1%) and Biontech SE-ADR (BNTX, 11.4%).
- Most Recent 13F
- Q2 2026
- Location
- NY, NY
- CIK
- 0002003147
- Portfolio Value
- $309.3M (Q4 2025)
- SEC Filing
- 0000905148-26-000704 ↗ filed Feb 13, 2026
Holdings Value
Holdings 14 stocks · $309.3M
| PFE Pfizer Inc. | 16.44% | 2,042,242 | $50.9M | — |
| REGN Regeneron Pharmaceuticals | 13.08% | 52,420 | $40.5M | — |
| BNTX Biontech SE-ADR | 11.43% | 371,216 | $35.3M | — |
| RPRX Royalty Pharma PLC Class A | 10.50% | 840,650 | $32.5M | — |
| ARGX Argenx SE - ADR | 9.70% | 35,685 | $30.0M | — |
| LEGN Legend Biotech Corp.-ADR | 7.43% | 1,056,668 | $23.0M | — |
| ROIV Roivant Sciences Ltd. | 7.21% | 1,028,298 | $22.3M | — |
| IONS Ionis Pharmaceuticals Inc. | 6.10% | 238,477 | $18.9M | — |
| NTRA Natera Inc. | 5.83% | 78,650 | $18.0M | — |
| LLY Eli Lilly & Co. | 2.89% | 8,307 | $8.9M | — |
| VRDN Viridian Therapeutics Inc. | 2.63% | 261,615 | $8.1M | — |
| MLYS Mineralys Therapeutics Inc. | 2.47% | 210,648 | $7.6M | — |
| CGON CG Oncology Inc. | 2.17% | 162,005 | $6.7M | — |
| ABVX Abivax SA-ADR | 2.11% | 48,502 | $6.5M | — |
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.